8 April 2026
Regenerative Medicine
From the moment blood enters the collection tube, a biological clock begins. This article examines how anticoagulant selection (ACD-A, ACD-B, sodium citrate, heparin, EDTA), storage temperature, and elapsed time each affect the therapeutic potency of platelet-rich plasma — with a detailed breakdown of the differential degradation rates of PDGF, TGF-β, VEGF, IGF-1, EGF, bFGF, and HGF, and evidence-based guidance on the clinical viability window.
Read article →
31 March 2026
Aesthetic Medicine
Higher doses of botulinum toxin type A do last longer — but the relationship is not linear. More units block more neuromuscular junctions, placing greater demand on axonal sprouting and SNAP-25 resynthesis during recovery. But beyond a dose threshold, the gains flatten sharply: a 50% increase in product rarely buys more than two additional weeks of duration. This article examines the biology behind dose-dependent duration, the shape of the dose-response curve, and why the economic case for higher dosing is often weaker than it appears.
Read article →
28 March 2026
Aesthetic Medicine
Brow ptosis — the descent of one or both brows after botulinum toxin treatment — is one of the more distressing outcomes of anti-wrinkle injections, and one of the least understood. It is most common in patients with low frontalis reserve who rely on chronic muscle recruitment simply to hold their brows at rest. Critically, it is not the same as eyelid ptosis — a distinction that matters because the management is entirely different. This article explains the anatomy behind why it happens, who is most susceptible, why female patients notice it most acutely through the difficulty of applying eye makeup, how a corrective injection into the orbicularis oculi can often rescue the result, and why — in the worst case — it always resolves within the standard botulinum toxin treatment window.
Read article →
19 February 2026
Hair Loss
Testosterone prescriptions in men aged 40 to 64 tripled between 2001 and 2011, and the trend has continued. With more men on TRT than ever before, a clinically important question has followed: does testosterone replacement accelerate hair loss? This article covers the testosterone-to-DHT conversion pathway via 5α-reductase, the follicular biology that drives TRT-associated androgenetic alopecia, how delivery method affects DHT levels, and the full range of treatment options — including 5α-reductase inhibitors, minoxidil, and topical finasteride — that can be used concurrently with testosterone therapy.
Read article →
14 January 2026
Aesthetic Medicine
A small but clinically significant subset of patients develop neutralising antibodies to botulinum toxin type A, progressively diminishing or eliminating treatment response over time. This article covers the immunology of NAB formation, the critical distinction between primary and secondary non-response, risk factors including dose, retreatment interval and booster injections, how to diagnose true immunoresistance using the Frontalis Antibody Test, and the management options — including treatment holidays, switching to BTX-B, and low-protein formulations such as Xeomin.
Read article →
8 December 2025
Aesthetic Medicine
Primary focal hyperhidrosis affects an estimated 2.8% of the population and causes significant social and occupational impairment. Botulinum toxin type A is TGA-approved for axillary hyperhidrosis and backed by strong RCT evidence — achieving a 93% response rate versus 36% for placebo. This article covers the cholinergic mechanism of eccrine gland suppression, axillary, palmar and plantar injection protocols, efficacy and duration data by anatomical site, the safety profile including compensatory sweating and transient hand weakness, and patient selection criteria.
Read article →
1 November 2025
Aesthetic Medicine
Topical lignocaine is routinely used before microneedling, botulinum toxin injections, PRP therapy, dermal fillers, and laser treatments — yet its application is frequently suboptimal. This comprehensive review covers the mechanism of voltage-gated sodium channel blockade, how formulation choice (EMLA, LMX, 4–5% compounded) and occlusion technique affect anaesthetic depth and onset, procedure-specific evidence, the important question of whether lignocaine interacts with PRP, and the full safety profile including local anaesthetic systemic toxicity (LAST) and methemoglobinemia risk.
Read article →
26 September 2025
Hair Loss
DHT is the most potent naturally occurring androgen in the human body — essential for male development in utero, responsible for virilisation at puberty, and the primary driver of androgenetic alopecia. This article covers DHT's biochemistry, synthesis, physiological roles across the lifespan, the paradox of scalp versus beard follicle response, and what the evidence actually shows about prostate and cardiovascular risk.
Read article →
21 August 2025
Hair Loss
Minoxidil was never intended to grow hair — its effect was discovered by accident in antihypertensive trials in the 1970s. This article traces the drug's history from its origins at the Upjohn Company to its current status as the world's most widely used hair loss treatment, covering mechanism of action, the genetics of SULT1A1 response variability, a topical vs oral comparison, dosing reference, and safety profile.
Read article →
16 July 2025
Hair Loss
Female pattern hair loss affects an estimated 40% of women by age 70 yet remains widely underdiagnosed. This comprehensive overview covers the hormonal pathophysiology, how FPHL differs from male pattern baldness, the Ludwig staging system, a structured diagnostic approach, and the full treatment spectrum — including topical and oral minoxidil, spironolactone, finasteride, PRP, and intradermal dutasteride mesotherapy.
Read article →
10 June 2025
Aesthetic Medicine
Dermal filler migration — the displacement of injectable HA beyond its intended anatomical placement — is more prevalent than early literature suggested, particularly in patients with long cumulative filler histories. This article explains why fillers move, identifies the highest-risk anatomical sites (lips, tear troughs, nasolabial folds, jawline), and outlines the role of hyaluronidase in management and a precision-first approach to prevention.
Read article →
5 May 2025
Aesthetic Medicine
Botulinum toxin type A provides facial muscle paralysis lasting three to six months on average — yet patients receiving identical doses frequently report very different durations. This article examines the key determinants: genetics, age, biological sex, exercise habits, injection technique, treatment history, metabolism, and immunogenicity, with practical implications for tailoring retreatment intervals.
Read article →
30 March 2025
Aesthetic Medicine
A gummy smile — characterised by 3 mm or more of gingival display on full smile — has a well-characterised muscular aetiology that responds predictably to botulinum toxin when patients are correctly selected. This article covers the anatomy of the lip elevator complex, the Yonsei and nasolabial injection approaches, conservative dosing protocols, adverse effects including smile asymmetry and 'joker smile', and the patient characteristics that predict the best outcomes.
Read article →
22 February 2025
Aesthetic Medicine
Botox complications are rare but real. When product diffuses into unintended muscles — causing eyelid or brow ptosis, smile asymmetry, or restricted lip movement — the experience is distressing but always temporary. This article explains how complications happen, how long each type takes to resolve, and why choosing a medically qualified doctor with formal anatomical training is the single most effective way to reduce your risk.
Read article →
18 January 2025
Aesthetic Medicine
Botox and Dysport are both TGA-approved botulinum toxin type A products, and both are effective — but they are not identical. Differences in protein complex size, diffusion profile, duration of effect, and unit dosing have real clinical consequences, particularly in facial aesthetics where millimetres of unwanted spread can cause ptosis, brow depression, or smile distortion. This article explains why Botox's more contained spread, slightly longer duration, and deep familiarity from hospital-based training make it the preferred product at this clinic.
Read article →
14 December 2024
Hair Loss
Prostaglandin D2 is elevated approximately threefold in balding scalp and directly inhibits follicular growth via the DP2 receptor — a mechanism entirely separate from the DHT axis that no existing approved therapy addresses. Topical 1% cetirizine applied once daily has demonstrated statistically significant improvements in hair density and shaft diameter in a randomised controlled trial, with outcomes broadly comparable to topical minoxidil at six months. This comprehensive review covers the PGD2/DP2 biology, full clinical trial data, step-by-step application technique, a month-by-month timeline of expected results, combination protocols with 5-ARIs, minoxidil and PRP, the complete side effect profile, and the prescribing framework in Australia.
Read article →
8 November 2024
Hair Loss
Initial hair shedding in the first weeks of minoxidil therapy is well-recognised in the topical literature — but does the same phenomenon apply to oral formulations? The mechanism is identical regardless of delivery route, yet the oral evidence base is based more on clinical extrapolation than prospective trial data. This article examines what the literature actually supports, and what patients should be told at the prescribing consultation.
Read article →
2 October 2024
Hair Loss
Dutasteride inhibits both type I and type II 5-alpha reductase, suppressing serum DHT by approximately 90% compared to 70% with finasteride. Multiple randomised controlled trials now demonstrate superior hair count outcomes with dutasteride 0.5mg versus finasteride 1mg — yet finasteride remains the more commonly prescribed agent. This article reviews the comparative evidence, side effect profiles, and the clinical case for dutasteride as first-line pharmacotherapy in androgenetic alopecia.
Read article →
Articles published here are intended for general informational and educational purposes. They do not constitute medical advice. Always consult a registered medical practitioner before commencing any treatment. References are provided within each article.